Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Study: Diabetes Drug Development is Riskier Compared to All Drug Development

By Marketwired | September 20, 2016

Diabetes drug development is riskier compared to all drug development, according to the Tufts Center for the Study of Drug Development.

Whereas scores of new diabetes and non-diabetes endocrine drugs have been launched since the mid-1990s, and the demand for new therapies continues to grow, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development, according to results of a new study conducted by the Tufts Center for the Study of Drug Development.

Only one in 13 investigational diabetes drugs that entered clinical testing from 1995 to 2007 ultimately received U.S. marketing approval, compared to one in eight of all investigational drugs, the study found.

Although diabetes drugs that enter the clinical pipeline are less likely to enter Phase III testing, compared to all drugs, once in Phase III, diabetes drugs enjoy slightly higher approval rates, according to Tufts CSDD.

“Creating new drugs to treat diabetes poses special development challenges, as reflected in part by Food and Drug Administration (FDA) regulatory guidelines promulgated in 2008 that require developers to demonstrate cardiovascular safety in large trials that include high-risk patients,” said Joseph A. DiMasi, director of economic analysis and research associate professor at the Tufts Center for the Study of Drug Development, who conducted the analysis.

He added, “Diabetes is a major cause of morbidity and mortality, and its incidence in the U.S., according to the Centers for Disease Control and Prevention, has tripled since 1980. Although there are numerous hypoglycemic agents on the market, there remains a strong need for new drugs that will reduce the human suffering and economic costs associated with this highly prevalent disease.”

The study examined the development pathways and characteristics for 27 diabetes and 34 non-diabetes endocrine drugs, which accounted for 10 percent of all FDA new therapeutic drug approvals during the 21-year period ending in 2015.

Key findings, reported in the September/October Tufts CSDD Impact Report, include the following:

  • Mean clinical development time for diabetes drugs increased by 1.3 years from 2002-2008 to 2009-2015.
  • Of the new diabetes drugs approved from 1995-2015, 15 percent received a priority review designation from the FDA, compared to 50 percent for non-diabetes endocrinedrugs and 46 percent for all non-endocrine drugs.
  • The likelihood that a diabetes drug entering clinical testing would transition to Phase III testing was 12.8 percent, vs. 21.1 percent for all drugs.
  • The likelihood of approval for a diabetes drug entering Phase III was 60 percent, compared to 56 percent for all drugs.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!  


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE